Base de dados : MEDLINE
Pesquisa : D27.505.696.399.472.161 [Categoria DeCS]
Referências encontradas : 22358 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2236 ir para página                         

  1 / 22358 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743567
[Au] Autor:Junior JFCR; Silva AS; Cardoso GA; Silvino VO; Martins MCC; Santos MAP
[Ad] Endereço:Universidade Federal do Piauí(UFPI), Campus Universitário Ministro Petrônio Portella, Department of Biophysics and Physiology, Teresina, PI, Brazil.
[Ti] Título:Androgenic-anabolic steroids inhibited post-exercise hypotension: a case control study.
[So] Source:Braz J Phys Ther;22(1):77-81, 2018 Jan - Feb.
[Is] ISSN:1809-9246
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: There is evidence of hypertensive effects caused by anabolic androgenic steroids (AAS). A single exercise session promotes the acute reduction of blood pressure, but the effects of AAS on this phenomenon are unknown. OBJECTIVES: To investigate the post-exercise blood pressure response in androgenic-anabolic steroid users. METHODS: Thirteen AAS users (23.9±4.3 years old) and sixteen controls (22.1±4.5 years old) performed a session of aerobic exercise. Heart rate and blood pressure were assessed before exercise and during a 60min post-exercise resting period. Repeated ANOVA measures were used to determine differences between the groups. RESULTS: While the control group had a significant reduction in post-exercise systolic blood pressure of up to 13.9±11.6mmHg at 40min, this phenomenon was limited among AAS users who reached a maximum of 6.2±11.5mmHg at 60min. The between groups comparison revealed significant higher post-exercise hypotension (PEH) for the control group at 30min (-12.9±14.1mmHg versus -2.9±7.6mmHg), 40min (-13.9±11.6mmHg versus -2.5±8.3mmHg), 50min (-13.9±13.9mmHg versus -5.0±7.9mmHg) and 60min (-12.5±12.8mmHg versus -6.2±11.5mmHg). There was no significant diastolic PEH in any of the groups. CONCLUSIONS: This study demonstrated impaired systolic post-exercise hypotension as a new adverse effect of AAS usage.
[Mh] Termos MeSH primário: Anabolizantes/uso terapêutico
Androgênios/uso terapêutico
Hipotensão Pós-Exercício/prevenção & controle
Hipotensão Pós-Exercício/fisiopatologia
Congêneres da Testosterona/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Anabolizantes/farmacologia
Androgênios/farmacologia
Pressão Sanguínea/efeitos dos fármacos
Estudos de Casos e Controles
Frequência Cardíaca/efeitos dos fármacos
Frequência Cardíaca/fisiologia
Seres Humanos
Sístole/efeitos dos fármacos
Sístole/fisiologia
Congêneres da Testosterona/farmacologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anabolic Agents); 0 (Androgens); 0 (Testosterone Congeners)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  2 / 22358 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28747362
[Au] Autor:Travers S; Martinerie L; Boileau P; Lombès M; Pussard E
[Ad] Endereço:Inserm, U1185, Le Kremlin-Bicêtre, France.
[Ti] Título:Alterations of adrenal steroidomic profiles in preterm infants at birth.
[So] Source:Arch Dis Child Fetal Neonatal Ed;103(2):F143-F151, 2018 Mar.
[Is] ISSN:1468-2052
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Preterm infants have relative adrenal and kidney immaturity. Recently, we linked their urine sodium loss to a hypoaldosteronism at variance with an appropriate stimulation of the renin-angiotensin system. To investigate this defective aldosterone secretion, we analyse the biosynthesis pathways of adrenal steroids in neonates according to gestational age (GA). DESIGN: Multicentre study (Premaldo) including 152 neonates classified into three groups: group 1 (very preterm (VPT)): <33 gestational weeks (GW); group 2 (preterm (PT)): 33-36 GW and group 3 (term (T)): ≥GW. METHOD: Steroidomic profiles of mineralocorticoids, glucocorticoids and adrenal androgens were established from umbilical cord at birth (n=152) and peripheral blood at day 3 (n=70) using a recently developed liquid chromatography mass spectrometry method (LC-MS/MS). The enzymatic activity of each biosynthesis step was estimated by the product-to-substrate ratio. RESULTS: At birth, VPT infants exhibit a global defect in adrenal steroid synthesis pathways leading to lower levels of aldosterone, cortisol and androstenedione than in term infants. This defect was strongly related to GA. On day 3, steroid precursors (progesterone, 11-deoxycorticosterone (DOC), 17-hydroxyprogesterone(17-OH-P) and 11-deoxycortisol (S)) were higher in VPT and negatively correlated with GA. Despite of precursors' accumulation, aldosterone and cortisol were similar in the three groups. At birth and day 3, a low cortisol/11-deoxycortisol ratio was found in preterm infants, suggesting an 11-beta-hydroxylase activity ( ) deficiency. CONCLUSIONS: At birth, VPT infants exhibit a global deficit in mineralocorticoids, glucocorticoids and adrenal androgens that attenuates on day 3 of life. Steroid profiling using LC-MS/MS provides evidence for a partial defect in 11-hydroxylase along with prematurity.
[Mh] Termos MeSH primário: Corticosteroides/metabolismo
Recém-Nascido Prematuro
[Mh] Termos MeSH secundário: Corticosteroides/sangue
Androgênios/metabolismo
Cromatografia Líquida
Sistema Enzimático do Citocromo P-450/metabolismo
Sangue Fetal/química
Idade Gestacional
Glucocorticoides/metabolismo
Seres Humanos
Hipoaldosteronismo/metabolismo
Lactente Extremamente Prematuro
Recém-Nascido
Mineralocorticoides/metabolismo
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Androgens); 0 (Glucocorticoids); 0 (Mineralocorticoids); 9035-51-2 (Cytochrome P-450 Enzyme System)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.1136/archdischild-2016-312457


  3 / 22358 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29372682
[Au] Autor:Kmetová Sivonová M; Jureceková J; Tatarková Z; Kaplán P; Lichardusová L; Hatok J
[Ad] Endereço:Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia. sivonova@jfmed.uniba.sk.
[Ti] Título:The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition.
[So] Source:Gen Physiol Biophys;36(5):487-499, 2017 Dec.
[Is] ISSN:0231-5882
[Cp] País de publicação:Slovakia
[La] Idioma:eng
[Ab] Resumo:Androgens play an important role during the development of both normal prostate epithelium and prostate cancer and variants of genes involved in androgen metabolism may be related to an increased risk of prostate disease. Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) is a key regulatory enzyme in the steroidogenic pathway; it catalyses both 17α-hydroxylase and 17,20-lyase activities and is essential for the production of both androgens and glucocorticoids. In this review, we focus on the structure and enzymatic activity of CYP17A1 and the mechanism of modulation of CYP17A1 activities. We discuss the relationship between common genetic variations in CYP17A1 gene and prostate cancer risk and the main effects of these variations on the prediction of susceptibility and clinical outcomes of prostate cancer patients. The mechanism of action, the efficacy and the clinical potential of CYP17A1 inhibitors in prostate cancer are also summarized.
[Mh] Termos MeSH primário: Androgênios/metabolismo
Glucocorticoides/metabolismo
Neoplasias da Próstata/genética
Neoplasias da Próstata/metabolismo
Esteroide 17-alfa-Hidroxilase/genética
Esteroide 17-alfa-Hidroxilase/metabolismo
[Mh] Termos MeSH secundário: Animais
Biomarcadores Tumorais/química
Biomarcadores Tumorais/genética
Biomarcadores Tumorais/metabolismo
Marcadores Genéticos/genética
Predisposição Genética para Doença/genética
Seres Humanos
Masculino
Modelos Biológicos
Neoplasias da Próstata/tratamento farmacológico
Esteroide 17-alfa-Hidroxilase/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Androgens); 0 (Biomarkers, Tumor); 0 (Genetic Markers); 0 (Glucocorticoids); EC 1.14.14.19 (CYP17A1 protein, human); EC 1.14.14.19 (Steroid 17-alpha-Hydroxylase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180127
[St] Status:MEDLINE
[do] DOI:10.4149/gpb_2017024


  4 / 22358 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29330226
[Au] Autor:Chortis V; Johal NJ; Bancos I; Evans M; Skordilis K; Guest P; Cullen MH; Porfiri E; Arlt W
[Ad] Endereço:Institute of Metabolism and Systems ResearchUniversity of Birmingham, Birmingham, UK.
[Ti] Título:Mitotane treatment in patients with metastatic testicular Leydig cell tumor associated with severe androgen excess.
[So] Source:Eur J Endocrinol;178(3):K21-K27, 2018 Mar.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mitotane (o,p'DDD) is established in the adjuvant and advanced-stage treatment of adrenocortical carcinoma and counteracts both tumor growth and tumor-related steroid production. Both the adrenal glands and the gonads are steroidogenically active organs and share a common embryogenic origin. Here, we describe the effects of mitotane in two patients with metastatic Leydig cell tumor (LCT) of the testes and associated severe androgen excess (serum testosterone 93 and 88 nmol/L, respectively; male reference range 7-27 nmol/L). Both men suffered from severe restlessness, insomnia and irritability, which they described as intolerable and disrupting normal life activities. Urinary steroid profiling by gas chromatography-mass spectrometry (GC-MS) confirmed excess androgen production and revealed concurrent overproduction of glucocorticoids and glucocorticoid precursors, which under physiological conditions are produced only by the adrenal glands but not by the gonads. In a palliative approach, they were commenced on mitotane, which achieved swift control of the hormone excess and the debilitating clinical symptoms, restoring normal quality of life. GC-MS demonstrated normalization of steroid production and decreased 5α-reductase activity, resulting in decreased androgen activation, and imaging demonstrated disease stabilization for 4-10 months. In conclusion, mitotane can be highly effective in controlling steroid excess in metastatic LCTs, with anti-tumor activity in some cases.
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/uso terapêutico
Hiperandrogenismo/tratamento farmacológico
Tumor de Células de Leydig/tratamento farmacológico
Mitotano/uso terapêutico
Neoplasias Testiculares/tratamento farmacológico
[Mh] Termos MeSH secundário: 3-Oxo-5-alfa-Esteroide 4-Desidrogenase/metabolismo
Androgênios/biossíntese
Cromatografia Gasosa-Espectrometria de Massas
Seres Humanos
Hiperandrogenismo/etiologia
Tumor de Células de Leydig/complicações
Tumor de Células de Leydig/secundário
Masculino
Meia-Idade
Metástase Neoplásica
Qualidade de Vida
Neoplasias Testiculares/complicações
Neoplasias Testiculares/patologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens); 0 (Antineoplastic Agents, Hormonal); 78E4J5IB5J (Mitotane); EC 1.3.99.5 (3-Oxo-5-alpha-Steroid 4-Dehydrogenase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180114
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0542


  5 / 22358 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465296
[Au] Autor:Nyquist MD; Corella A; Burns J; Coleman I; Gao S; Tharakan R; Riggan L; Cai C; Corey E; Nelson PS; Mostaghel EA
[Ad] Endereço:Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
[Ti] Título:Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.
[So] Source:Mol Cancer Res;15(5):521-531, 2017 05.
[Is] ISSN:1557-3125
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Androgen receptor (AR) signaling is fundamental to prostate cancer and is the dominant therapeutic target in metastatic disease. However, stringent androgen deprivation therapy regimens decrease quality of life and have been largely unsuccessful in curtailing mortality. Recent clinical and preclinical studies have taken advantage of the dichotomous ability of AR signaling to elicit growth-suppressive and differentiating effects by administering hyperphysiologic levels of testosterone. In this study, high-throughput drug screening identified a potent synergy between high-androgen therapy and YM155, a transcriptional inhibitor of survivin (BIRC5). This interaction was mediated by the direct transcriptional upregulation of the YM155 transporter SLC35F2 by the AR. Androgen-mediated YM155-induced cell death was completely blocked by the overexpression of multidrug resistance transporter ABCB1. SLC35F2 expression was significantly correlated with intratumor androgen levels in four distinct patient-derived xenograft models, and with AR activity score in a large gene expression dataset of castration-resistant metastases. A subset of tumors had significantly elevated SLC35F2 expression and, therefore, may identify patients who are highly responsive to YM155 treatment. IMPLICATIONS: The combination of androgen therapy with YM155 represents a novel drug synergy, and SLC35F2 may serve as a clinical biomarker of response to YM155.
[Mh] Termos MeSH primário: Androgênios/administração & dosagem
Imidazóis/administração & dosagem
Proteínas de Membrana Transportadoras/genética
Naftoquinonas/administração & dosagem
Neoplasias da Próstata/tratamento farmacológico
Receptores Androgênicos/metabolismo
[Mh] Termos MeSH secundário: Androgênios/farmacologia
Animais
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Sinergismo Farmacológico
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Imidazóis/farmacologia
Masculino
Camundongos
Naftoquinonas/farmacologia
Neoplasias da Próstata/genética
Neoplasias da Próstata/metabolismo
Transdução de Sinais/efeitos dos fármacos
Testosterona/administração & dosagem
Testosterona/farmacologia
Resultado do Tratamento
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AR protein, human); 0 (Androgens); 0 (Imidazoles); 0 (Membrane Transport Proteins); 0 (Naphthoquinones); 0 (Receptors, Androgen); 0 (SLC35F2 protein, human); 0 (YM 155); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1158/1541-7786.MCR-16-0315-T


  6 / 22358 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29339527
[Au] Autor:Ghanim H; Dhindsa S; Abuaysheh S; Batra M; Kuhadiya ND; Makdissi A; Chaudhuri A; Dandona P
[Ad] Endereço:Division of Endocrinology, Diabetes and MetabolismState University of New York at Buffalo, Williamsville, New York, USA.
[Ti] Título:Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone.
[So] Source:Eur J Endocrinol;178(3):277-283, 2018 Mar.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: One-third of males with type 2 diabetes (T2DM) have hypogonadism, characterized by low total and free testosterone concentrations. We hypothesized that this condition is associated with a compensatory increase in the expression of androgen receptors (AR) and that testosterone replacement reverses these changes. We also measured estrogen receptor and aromatase expression. MATERIALS AND METHODS: This is a randomized double-blind placebo-controlled trial. Thirty-two hypogonadal and 32 eugonadal men with T2DM were recruited. Hypogonadal men were randomized to receive intramuscular testosterone or saline every 2 weeks for 22 weeks. We measured AR, ERα and aromatase expression in peripheral blood mononuclear cells (MNC), adipose tissue and skeletal muscle in hypogonadal and eugonadal males with T2DM at baseline and after 22 weeks of treatment in those with hypogonadism. RESULTS: The mRNA expression of and aromatase in adipose tissue from hypogonadal men was significantly lower as compared to eugonadal men, and it increased significantly to levels comparable to those in eugonadal patients with T2DM following testosterone treatment. mRNA expression was also significantly lower in MNC from hypogonadal patients compared to eugonadal T2DM patients. Testosterone administration in hypogonadal patients also restored mRNA and nuclear extract protein levels from MNC to that in eugonadal patients. In the skeletal muscle, AR mRNA and protein expression are lower in men with hypogonadism. Testosterone treatment restored AR expression levels to that comparable to levels in eugonadal men. CONCLUSIONS: We conclude that, contrary to our hypothesis, the expression of AR, ERα and aromatase is significantly diminished in hypogonadal men as compared to eugonadal men with type 2 diabetes. Following testosterone replacement, there is a reversal of these deficits.
[Mh] Termos MeSH primário: Androgênios/uso terapêutico
Aromatase/genética
Diabetes Mellitus Tipo 2/metabolismo
Receptor alfa de Estrogênio/genética
Hipogonadismo/tratamento farmacológico
Leucócitos Mononucleares/metabolismo
Receptores Androgênicos/genética
Testosterona/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Aromatase/metabolismo
Western Blotting
Diabetes Mellitus Tipo 2/complicações
Método Duplo-Cego
Receptor alfa de Estrogênio/metabolismo
Seres Humanos
Hipogonadismo/complicações
Hipogonadismo/genética
Hipogonadismo/metabolismo
Masculino
Meia-Idade
RNA Mensageiro/metabolismo
Reação em Cadeia da Polimerase em Tempo Real
Receptores Androgênicos/metabolismo
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Gordura Subcutânea/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (AR protein, human); 0 (Androgens); 0 (Estrogen Receptor alpha); 0 (RNA, Messenger); 0 (Receptors, Androgen); 0 (estrogen receptor alpha, human); 3XMK78S47O (Testosterone); EC 1.14.14.1 (Aromatase); EC 1.14.14.1 (CYP19A1 protein, human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0673


  7 / 22358 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29289696
[Au] Autor:Passoni MT; Kristensen MN; Morais RN; Woitkowiak C; Boareto AC; da Silva Amaral BA; Grechi N; Dalsenter PR; Munkboel CH; Styrishave B; Kristensen DM; Gomes C; van Ravenzwaay B; Martino-Andrade AJ
[Ad] Endereço:Department of Pharmacology, Reproductive Toxicology Laboratory, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
[Ti] Título:Assessment of the analgesic dipyrone as a possible (anti)androgenic endocrine disruptor.
[So] Source:Toxicol Lett;285:139-147, 2018 Mar 15.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Mild analgesics have been associated with antiandrogenic effects, but there are no such studies on dipyrone, despite its high prevalence of use in many countries. We examined the production of steroid hormones in human H295R cells after exposure to dipyrone and two metabolites, 4-Methylaminoantipyrine (MAA) and 4-Aminoantipyrine (AA), as well as fetal testicular testosterone production in rats following maternal dipyrone exposure. Androgen agonistic/antagonistic effects were examined in vitro for dipyrone and its metabolites in the Yeast Androgen Screen (YAS) assay and in vivo for dipyrone through the Hershberger assay. In vitro we tested dipyrone, MAA, and AA (0.1-1000 µM) while in vivo we used dipyrone (50, 100, 200 mg/kg/day). In the H295R assay, dipyrone, MAA and AA reduced the production of androgens and corticosteroids. Testosterone was reduced at concentrations 4-13 times higher than the maximum plasma concentrations reported in humans for MAA and AA. No effects were observed in the fetal testosterone production assay. In the YAS and Hershberger assays, no androgen agonistic/antagonistic activities were observed. These results indicate that dipyrone and its metabolites do not interact with the androgen receptor, but have the potential to inhibit steroidogenesis, however only at concentrations that are not relevant under normal medical use.
[Mh] Termos MeSH primário: Analgésicos/toxicidade
Antagonistas de Receptores de Andrógenos/toxicidade
Androgênios/toxicidade
Dipirona/toxicidade
Disruptores Endócrinos/toxicidade
[Mh] Termos MeSH secundário: Analgésicos/sangue
Antagonistas de Receptores de Andrógenos/sangue
Androgênios/sangue
Animais
Bioensaio
Linhagem Celular Tumoral
Dipirona/sangue
Disruptores Endócrinos/sangue
Feminino
Seres Humanos
Masculino
Gravidez
Efeitos Tardios da Exposição Pré-Natal/sangue
Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente
Ratos
Ratos Wistar
Receptores Androgênicos/genética
Receptores Androgênicos/metabolismo
Testículo/efeitos dos fármacos
Testículo/embriologia
Testículo/metabolismo
Testosterona/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Androgen Receptor Antagonists); 0 (Androgens); 0 (Endocrine Disruptors); 0 (Receptors, Androgen); 3XMK78S47O (Testosterone); 6429L0L52Y (Dipyrone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180101
[St] Status:MEDLINE


  8 / 22358 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28978410
[Au] Autor:Wolf TE; Schaebs FS; Bennett NC; Burroughs R; Ganswindt A
[Ad] Endereço:Endocrine Research Laboratory, Department of Anatomy and Physiology, Faculty of Veterinary Science, University of Pretoria, Onderstepoort 0110, South Africa; Department of Animal, Wildlife and Grassland Sciences, Faculty of Natural and Agricultural Sciences, University of the Free State, Bloemfontei
[Ti] Título:Age and socially related changes in fecal androgen metabolite concentrations in free-ranging male giraffes.
[So] Source:Gen Comp Endocrinol;255:19-25, 2018 Jan 01.
[Is] ISSN:1095-6840
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In many mammal species, androgen levels in males are elevated during periods of mating activity, often to facilitate aggressive behavior between males over access to fertile females. However, this pattern might be less obvious in species with a rather low male-male aggression rate, or in those that are not strictly seasonal breeders. A complex social structure, as well as additional social and environmental factors, might add more to the complexity. Here, we applied a non-invasive method to monitor fecal androgen metabolite (fAM) levels in free-ranging giraffe bulls over a period of months to examine longitudinal patterns of androgen metabolite concentrations in relation to observed male sexual behavior in different age classes. Giraffes are non-seasonal breeders, living in a fission-fusion social system and males show a roaming strategy to search for fertile females. Our results show that season has an impact on fAM levels in free-ranging giraffes, with respective steroid concentrations being higher in summer. In the presence of females, fAM levels of bulls are significantly higher compared to when found in all-male groups, with old adult bulls showing the highest fAM levels. In contrast, young adult bulls have overall slightly higher fAM levels compared to old adult bulls when residing in all male groups. Sexual behavior increases fAM levels only in old adult bulls.
[Mh] Termos MeSH primário: Envelhecimento/fisiologia
Androgênios/metabolismo
Fezes/química
Girafas/metabolismo
Metaboloma
Comportamento Social
[Mh] Termos MeSH secundário: Animais
Comportamento Animal
Feminino
Masculino
Modelos Biológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171006
[St] Status:MEDLINE


  9 / 22358 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29250542
[Au] Autor:Fu C; Zeng Q; Li F; Wang H; Sun J; Wang H
[Ad] Endereço:College of Animal Science and Technology, Shandong Agricultural University, Tai'an 271018, China.
[Ti] Título:Comparative Transcriptome Analysis Reveals Related Regulatory Mechanisms of Androgenic Gland in .
[So] Source:Biomed Res Int;2017:4956216, 2017.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Chinese mitten crab is one of the most commercially important aquaculture species in China. The androgenic gland (AG) of crustaceans plays pivotal roles in the regulation of male differentiation and in maintaining the male sexual characteristics. In order to reveal related mechanisms in AG, we compared transcriptomes of AG between proliferation and secretion phase. A total of 72,000 unigenes and 4,027 differentially expressed genes were obtained. Gene ontology enrichment analysis indicated that biological processes and metabolic pathways related to protein synthesis and secretion such as transcription, translation, and signal transduction were significantly enriched. Critical genes such as , and were identified and potentially involved in maintaining the testis development and spermatogenesis. Ribosomes pathway revealed the cause of insulin-like androgenic gland hormone secretion increase. Three insulin-like receptors were thought to be associated with growth and spermatogenesis. In the neuroactive ligand-receptor interaction pathway, the expression of octopamine receptor, 5-HT receptor 1, and melatonin receptor was significantly changed, which revealed the key regulation mechanism of aggressive and mating behavior of males. Comparative transcriptome analysis provided new insights into the genome-wide molecular mechanisms of AG development and the regulatory mechanisms of male development.
[Mh] Termos MeSH primário: Androgênios/metabolismo
Braquiúros/fisiologia
Regulação da Expressão Gênica/fisiologia
Transcriptoma/fisiologia
[Mh] Termos MeSH secundário: Animais
Braquiúros/genética
Perfilação da Expressão Gênica
Regulação da Expressão Gênica/genética
Ontologia Genética
Masculino
Comportamento Sexual Animal/fisiologia
Transdução de Sinais
Transcriptoma/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.1155/2017/4956216


  10 / 22358 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455078
[Au] Autor:Diamond MP; Legro RS; Coutifaris C; Alvero R; Robinson RD; Casson PA; Christman GM; Huang H; Hansen KR; Baker V; Usadi R; Seungdamrong A; Bates GW; Rosen RM; Schlaff W; Haisenleder D; Krawetz SA; Barnhart K; Trussell JC; Santoro N; Eisenberg E; Zhang H; Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Medicine Network
[Ad] Endereço:Department of Obstetrics and Gynecology, Georgia Regents University, Augusta, GA; Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI. Electronic address: michael.diamond@augusta.edu.
[Ti] Título:Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility.
[So] Source:Am J Obstet Gynecol;217(2):191.e1-191.e19, 2017 08.
[Is] ISSN:1097-6868
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: While female sexual dysfunction is a frequent occurrence, characteristics in infertile women are not well delineated. Furthermore, the impact of infertility etiology on the characteristics in women with differing androgen levels observed in women with polycystic ovary syndrome and unexplained infertility has not been assessed. OBJECTIVE: The objective of the study was to determine the characteristics of sexual dysfunction in women with polycystic ovary syndrome and unexplained infertility. STUDY DESIGN: A secondary data analysis was performed on 2 of Eunice Kennedy Shriver National Institute of Child Health and Human Development Cooperative Reproductive Medicine Networks clinical trials: Pregnancy in Polycystic Ovary Syndrome Study II and Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation. Both protocols assessed female sexual function using the Female Sexual Function Inventory and the Female Sexual Distress Scale. RESULTS: Women with polycystic ovary syndrome had higher weight and body mass index than women with unexplained infertility (each P < .001), greater phenotypic (Ferriman-Gallwey hirsutism score, sebum score, and acne score; each P < .001), and hormonal (testosterone, free testosterone, and dehydroepiandrosterone; each P < .001) evidence of androgen excess. Sexual function scores, as assessed by the Female Sexual Function Inventory, were nearly identical. The Female Sexual Distress Scale total score was higher in women with polycystic ovary syndrome. The mean Female Sexual Function Inventory total score increased slightly as the free androgen index increased, mainly as a result of the desire subscore. This association was more pronounced in the women with unexplained infertility. CONCLUSION: Reproductive-age women with infertility associated with polycystic ovary syndrome and unexplained infertility, despite phenotypic and biochemical differences in androgenic manifestations, do not manifest clinically significant differences in sexual function.
[Mh] Termos MeSH primário: Infertilidade Feminina/complicações
Síndrome do Ovário Policístico/complicações
Disfunções Sexuais Fisiológicas/etiologia
[Mh] Termos MeSH secundário: Adulto
Androgênios/sangue
Estudos Transversais
Feminino
Seres Humanos
Infertilidade Feminina/sangue
Síndrome do Ovário Policístico/sangue
Disfunções Sexuais Fisiológicas/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Androgens)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE



página 1 de 2236 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde